Literature DB >> 32067357

Complex interactions underlie racial disparity in the risk of developing Alzheimer's disease dementia.

Chengjie Xiong1,2, Jingqin Luo1,3,4, Dean Coble1,2, Folasade Agboola1,2, Walter Kukull5,6, John C Morris2,7,8.   

Abstract

INTRODUCTION: We aim to determine racial disparities and their modifying factors in risk for Alzheimer's disease (AD) dementia among cognitively normal individuals 65 years or older.
METHODS: Longitudinal data from the National Alzheimer's Coordinating Center Uniform Data Set on 1229 African Americans (AAs) and 6679 whites were analyzed for the risk of AD using competing risk models with death as a competing event.
RESULTS: Major AD risk factors modified racial differences which, when statistically significant, occurred only with older age among APOE ε4 negative individuals, but also with younger age among APOE ε4 positive individuals. The racial differences favored AAs among individuals with body mass index (BMI) < 30, but whites among individuals with a high BMI (≥ 30), and were additionally modified by sex, education, hypertension, and smoking status.
CONCLUSIONS: The presence, direction, and relative magnitude of racial disparity for AD represent an interactive function of major AD and cerebrovascular risk factors.
© 2020 the Alzheimer's Association.

Entities:  

Keywords:  competing risk survival model; interactions; racial disparity; risk of Alzheimer's disease

Mesh:

Substances:

Year:  2020        PMID: 32067357      PMCID: PMC7259475          DOI: 10.1002/alz.12060

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  29 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Inequalities in dementia incidence between six racial and ethnic groups over 14 years.

Authors:  Elizabeth Rose Mayeda; M Maria Glymour; Charles P Quesenberry; Rachel A Whitmer
Journal:  Alzheimers Dement       Date:  2016-02-11       Impact factor: 21.566

3.  The National Alzheimer's Coordinating Center (NACC) Database: an Alzheimer disease database.

Authors:  Duane L Beekly; Erin M Ramos; Gerald van Belle; Woodrow Deitrich; Amber D Clark; Mary E Jacka; Walter A Kukull
Journal:  Alzheimer Dis Assoc Disord       Date:  2004 Oct-Dec       Impact factor: 2.703

4.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Authors:  Anne M Fagan; Catherine M Roe; Chengjie Xiong; Mark A Mintun; John C Morris; David M Holtzman
Journal:  Arch Neurol       Date:  2007-01-08

5.  Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease.

Authors:  J L Price; A I Ko; M J Wade; S K Tsou; D W McKeel; J C Morris
Journal:  Arch Neurol       Date:  2001-09

6.  The Clinical Dementia Rating (CDR): current version and scoring rules.

Authors:  J C Morris
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

7.  Racial differences in the etiology of dementia and frequency of Alzheimer lesions in the brain.

Authors:  S M de la Monte; G M Hutchins; G W Moore
Journal:  J Natl Med Assoc       Date:  1989-06       Impact factor: 1.798

8.  Racial differences in the progression of cognitive decline in Alzheimer disease.

Authors:  Lisa L Barnes; Robert S Wilson; Yan Li; Neelum T Aggarwal; David W Gilley; Judith J McCann; Denis A Evans
Journal:  Am J Geriatr Psychiatry       Date:  2005-11       Impact factor: 4.105

9.  Race modifies the relationship between cognition and Alzheimer's disease cerebrospinal fluid biomarkers.

Authors:  Jennifer C Howell; Kelly D Watts; Monica W Parker; Junjie Wu; Alexander Kollhoff; Thomas S Wingo; Cornelya D Dorbin; Deqiang Qiu; William T Hu
Journal:  Alzheimers Res Ther       Date:  2017-11-02       Impact factor: 6.982

10.  The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort.

Authors:  Pierre N Tariot; Francisco Lopera; Jessica B Langbaum; Ronald G Thomas; Suzanne Hendrix; Lon S Schneider; Silvia Rios-Romenets; Margarita Giraldo; Natalia Acosta; Carlos Tobon; Claudia Ramos; Alejandro Espinosa; William Cho; Michael Ward; David Clayton; Michael Friesenhahn; Howard Mackey; Lee Honigberg; Sandra Sanabria Bohorquez; Kewei Chen; Trisha Walsh; Carolyn Langlois; Eric M Reiman
Journal:  Alzheimers Dement (N Y)       Date:  2018-03-08
View more
  9 in total

1.  Perspective on the "African American participation in Alzheimer disease research: Effective strategies" workshop, 2018.

Authors:  Andrea Denny; Marissa Streitz; Kristin Stock; Joyce E Balls-Berry; Lisa L Barnes; Goldie S Byrd; Raina Croff; Sujuan Gao; Crystal M Glover; Hugh C Hendrie; William T Hu; Jennifer J Manly; Krista L Moulder; Susan Stark; Stephen B Thomas; Rachel Whitmer; Roger Wong; John C Morris; Jennifer H Lingler
Journal:  Alzheimers Dement       Date:  2020-08-17       Impact factor: 21.566

2.  Development of a Comprehensive Battery to Collect Social and Structural Determinants of Health (SSDOH) in Cognitively Normal or Very Mildly Impaired Persons.

Authors:  Marissa L Streitz; Andrea Denny; Chengjie Xiong; Lena McCue; Shana D Stites; Sharnita Midgett; Dawn Mechanic-Hamilton; Krista L Moulder; John C Morris; Joyce Balls-Berry
Journal:  Alzheimer Dis Assoc Disord       Date:  2022-04-06       Impact factor: 2.357

3.  The complex relationship between depression and progression to incident cognitive impairment across race and ethnicity.

Authors:  Ganesh M Babulal; Yiqi Zhu; Catherine M Roe; Darrell L Hudson; Monique M Williams; Samantha A Murphy; Jason Doherty; Ann M Johnson; Jean-Francois Trani
Journal:  Alzheimers Dement       Date:  2022-02-25       Impact factor: 16.655

4.  Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults.

Authors:  Chengjie Xiong; Jingqin Luo; Suzanne E Schindler; Anne M Fagan; Tammie Benzinger; Jason Hassenstab; Joyce E Balls-Berry; Folasade Agboola; Elizabeth Grant; Krista L Moulder; John C Morris
Journal:  Alzheimers Dement       Date:  2022-02-25       Impact factor: 16.655

5.  Risk of Alzheimer's disease and related dementia by sex and race/ethnicity: The Multiethnic Cohort Study.

Authors:  Unhee Lim; Songren Wang; Song-Yi Park; David Bogumil; Anna H Wu; Iona Cheng; Christopher A Haiman; Loïc Le Marchand; Lynne R Wilkens; Lon White; V Wendy Setiawan
Journal:  Alzheimers Dement       Date:  2021-12-09       Impact factor: 16.655

6.  African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants.

Authors:  Suzanne E Schindler; Carlos Cruchaga; Amulya Joseph; Lena McCue; Fabiana H G Farias; Consuelo H Wilkins; Yuetiva Deming; Rachel L Henson; Robert J Mikesell; Laura Piccio; Jorge J Llibre-Guerra; Krista L Moulder; Anne M Fagan; Beau M Ances; Tammie L S Benzinger; Chengjie Xiong; David M Holtzman; John C Morris
Journal:  Neurol Genet       Date:  2021-03-04

7.  Black-White variation in the relationship between early educational experiences and trajectories of cognitive function among US-born older adults.

Authors:  Katrina M Walsemann; Eleanor M Kerr; Jennifer A Ailshire; Pamela Herd
Journal:  SSM Popul Health       Date:  2022-07-31

Review 8.  Dysregulation of Endothelin-1: Implications for Health Disparities in Alzheimer's Disease.

Authors:  Donald J Alcendor
Journal:  J Pers Med       Date:  2020-10-28

Review 9.  Epigallocatechin-3-Gallate (EGCG): New Therapeutic Perspectives for Neuroprotection, Aging, and Neuroinflammation for the Modern Age.

Authors:  Ashley Payne; Samuel Nahashon; Equar Taka; Getinet M Adinew; Karam F A Soliman
Journal:  Biomolecules       Date:  2022-02-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.